Literature DB >> 10350002

Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.

S D Raeissi1, I J Hidalgo, J Segura-Aguilar, P Artursson.   

Abstract

PURPOSE: To further characterize cytochrome P450 (CYP) and P-glycoprotein (Pgp) expression in monolayers of the Caco-2 cell clone TC7, a cell culture model of the human intestinal epithelium. To study the interplay between CYP3A and Pgp as barriers to intestinal drug absorption in TC7 cells using terfenadine and its metabolites as substrates.
METHODS: mRNA expression of eight CYPs and Pgp was investigated in TC7 and parental Caco-2 (Caco-2p) cell monolayers using RT-PCR. The CYP3A kinetics was determined in microsomes from both cell lines. The transport, metabolism and efflux of terfenadine and its metabolites were investigated in TC7 monolayers.
RESULTS: Both TC7 and Caco-2p cells expressed mRNA for Pgp and several important CYPs. However, mRNA for CYP3A4 was detectable anly from TC7 cells. The relative affinity of CYP3A for terfenadine metabolism in the two cell lines was comparable, but the maximum reaction rate in the TC7 cells was 8-fold higher. The rate of transport of terfenadine and its metabolites hydroxy-terfenadine (HO-T) and azacyclonol across TC7 monolayers was 7.1-, 3.5- and 2.1-fold higher, respectively, in the basolateral to apical direction than it was in the apical to basolateral (AP-BL) direction. Inhibition studies indicated that the efflux was mediated by Pgp. Ketoconazole increased the AP-BL transport terfenadine dramatically by inhibiting both terfenadine metabolism and Pgp efflux.
CONCLUSIONS: Cell culture models such as TC7 provide qualitative information on drug interactions involving intestinal CYP3A and Pgp.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350002     DOI: 10.1023/a:1018851919674

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Expression of cytochrome P-450 3A in HT29-MTX cells and Caco-2 clone TC7.

Authors:  V Carrière; T Lesuffleur; A Barbat; M Rousset; E Dussaulx; P Costet; I de Waziers; P Beaune; A Zweibaum
Journal:  FEBS Lett       Date:  1994-12-05       Impact factor: 4.124

2.  Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.

Authors:  P Schmiedlin-Ren; K E Thummel; J M Fisher; M F Paine; K S Lown; P B Watkins
Journal:  Mol Pharmacol       Date:  1997-05       Impact factor: 4.436

Review 3.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

Authors:  V J Wacher; C Y Wu; L Z Benet
Journal:  Mol Carcinog       Date:  1995-07       Impact factor: 4.784

4.  Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects.

Authors:  M G Mercurio; S J Shiff; R A Galbraith; S Sassa
Journal:  Biochem Biophys Res Commun       Date:  1995-05-16       Impact factor: 3.575

5.  CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines.

Authors:  L Gervot; V Carrière; P Costet; P H Cugnenc; A Berger; P H Beaune; I de Waziers
Journal:  Environ Toxicol Pharmacol       Date:  1996-12-20       Impact factor: 4.860

6.  Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Authors:  K S Lown; R R Mayo; A B Leichtman; H L Hsiao; D K Turgeon; P Schmiedlin-Ren; M B Brown; W Guo; S J Rossi; L Z Benet; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

7.  Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells.

Authors:  W N Hait; J F Gesmonde; J R Murren; J M Yang; H X Chen; M Reiss
Journal:  Biochem Pharmacol       Date:  1993-01-26       Impact factor: 5.858

8.  CYP3A gene expression in human gut epithelium.

Authors:  J C Kolars; K S Lown; P Schmiedlin-Ren; M Ghosh; C Fang; S A Wrighton; R M Merion; P B Watkins
Journal:  Pharmacogenetics       Date:  1994-10

9.  Pharmacokinetics and biotransformation studies of terfenadine in man.

Authors:  D A Garteiz; R H Hook; B J Walker; R A Okerholm
Journal:  Arzneimittelforschung       Date:  1982

10.  Jejunal absorption and metabolism of R/S-verapamil in humans.

Authors:  R Sandström; A Karlsson; L Knutson; H Lennernäs
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

View more
  6 in total

1.  Physicochemical properties and transport of steroids across Caco-2 cells.

Authors:  Fried Faassen; Jan Kelder; Johan Lenders; Rob Onderwater; Herman Vromans
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

2.  Effect of five novel 5-substituted tetrandrine derivatives on P-glycoprotein-mediated inhibition and transport in Caco-2 cells.

Authors:  Zhonglian Cao; Dan Li; Li Liu; Ping Yang
Journal:  Oncol Lett       Date:  2018-09-24       Impact factor: 2.967

3.  Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

Authors:  Nathalie Perdaems; Helene Blasco; Cedric Vinson; Marylore Chenel; Sarah Whalley; Fanny Cazade; François Bouzom
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

Authors:  Leah Tong; Truc K Phan; Kelly L Robinson; Darius Babusis; Robert Strab; Siddhartha Bhoopathy; Ismael J Hidalgo; Gerald R Rhodes; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

5.  Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora.

Authors:  Zhen Yang; Jing-Rong Wang; Tao Niu; Song Gao; Taijun Yin; Ming You; Zhi-Hong Jiang; Ming Hu
Journal:  Drug Metab Dispos       Date:  2012-05-14       Impact factor: 3.922

6.  Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring.

Authors:  Gunilla Englund; Pär Hallberg; Per Artursson; Karl Michaëlsson; Håkan Melhus
Journal:  BMC Med       Date:  2004-04-02       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.